Physician profile
Allison Buczynski
NPI 1407498850
$3,195.72
in general payments reported to CMS, 2019-2025
25 companies · $39.87 in 2025
The $39.87 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,010 · 2022: $1,187 · 2023: $777 · 2024: $182 · 2025: $39.87.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $999.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $998.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $515.29 | 2021-2024 | Farxiga, Brilinta, Airsupra |
| Novartis Pharmaceuticals Corporation | $378.03 | 2021-2024 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $319.51 | 2021-2025 | Lifevest |
| Boehringer Ingelheim Pharmaceuticals, INC. | $274.57 | 2021-2023 | Jardiance |
| Amgen INC. | $248.84 | 2021-2023 | Repatha |
| Bayer Healthcare Pharmaceuticals INC. | $202.65 | 2022-2023 | |
| Janssen Pharmaceuticals, INC | $190.54 | 2021-2023 | Xarelto |
| Amarin Pharma, INC. | $153.17 | 2021-2023 | |
| Merck Sharp & Dohme LLC | $128.29 | 2021-2024 | Verquvo |
| Lilly USA, LLC | $111.50 | 2021-2023 | Mounjaro |
| Mylan Specialty L.P. | $108.12 | 2022-2024 | Yupelri |
| Sanofi-Aventis U.S. LLC | $84.53 | 2021-2023 | |
| Lexicon Pharmaceuticals, INC. | $83.32 | 2023-2024 | Inpefa |
| Abbvie INC. | $77.36 | 2022-2023 | |
| Daiichi Sankyo INC. | $62.69 | 2021-2023 | Injectafer |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $46.62 | 2022-2023 | Eliquis |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $43.21 | 2021-2022 | |
| Novo Nordisk INC | $42.74 | 2022-2023 | Ozempic, Rybelsus |
| Phathom Pharmaceuticals, INC. | $24.22 | 2024 | Voquezna |
| Actelion Pharmaceuticals US, INC. | $23.00 | 2021 | |
| Glaxosmithkline, LLC. | $20.00 | 2023 | Trelegy Ellipta |
| Shield Therapeutics INC | $18.79 | 2023 | Accrufer |
| Pfizer INC. | $14.56 | 2021 | |
| Medicomp INC | $12.68 | 2023 | Telepatch Cardiac Monitor |
| Esperion Therapeutics, INC. | $11.49 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Allison Buczynski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.